CCM DBio, PanGen set to launch biosimilars for kidney dialysis

CCM Duopharma Biotech Bhd (CCMDB) and PanGen Biotech, Inc. have completed their clinical trials for the biosimilar erythropoietin or EPO product which can be used in kidney dialysis.

Recombinant version of EPO is used as the therapeutic agent of all anemia patients, acute anemia in kidney dialysis patients, anemia due to anti-cancer chemotherapy and patients requiring blood transfusion.

CCMDB said through Duopharma’s investment into the RM18mil joint clinical trials, the latter obtained exclusive licence to package, fill & finish, and distribute the EPO product in Malaysia, Singapore and Brunei.